LNTII (lactose-N-trioseII) is an important member of the "family" of HMOs (human milk oligosaccharides), also known as "core sugar". It serves as a precursor for various human milk oligosaccharides including lactose-N-tetraose and lactose-N-neotetraose. Increasing experimental evidence demonstrates that lactose-N-trioseII plays a significant role in immune regulation, anti-inflammation, and the activation of NK cells.

In 2019, researchers at the medical center of University of Groningen in Netherlands confirmed through experiments that "human milk oligosaccharides and their acidic hydrolysate lactose-N-trioseII exhibit immune modulatory effects in a dose- and structure-dependent manner through TLRs". The study revealed that lactose-N-trioseII can activate NF-κB via the TLR pathway, indicating that lactose-N-trioseII has immune regulatory effects on immune cells such as macrophages. Similarly, another study from the same medical center, focusing on "lactose-N-trioseII inducing inflammation in fetal intestinal epithelial cells," showed that "lactose-N-trioseII can effectively reduce the incidence of inflammation by interacting with the intestinal epithelial cells of infants and adults."

Professor Fang Xu, founder and chief scientist of Henglu, successfully achieved large-scale production of lactose-N-trioseII using a proprietary enzymatic processing method, and the product has been validated by authoritative institutions. Its purity is up to 99.9%.